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Abstract : Background : Presepsin (P-SEP) is a highly specific sepsis marker, and its fluctuation with respect 
to advanced renal impairment or sample agitation has not been fully investigated. We evaluated several renal 
function-corrected P-SEP indices to establish a simple index and its reference range. Methods : Blood samples for 
P-SEP measurement were collected with minimal agitation. P-SEP levels were measured using the rapid auto-
mated immunoanalyzer “PATHFAST.” This study included 85 chronic kidney disease (CKD) patients, 65 healthy 
volunteers, and 4 sepsis patients. Results : Patients stratified by estimated glomerular filtration rate (GFR) had 
significantly higher P-SEP levels for CKD stage G3, especially the advanced GFR stage. We evaluated prese-
psin / creatinine (P-SEP / CRE) and P-SEP / eGFR ratios as possible indices for renal function. The P-SEP / CRE 
ratio exhibited no increase correlating with the GFR stage and was identical in the normal and CKD groups ; 
P-SEP / eGFR decreased if GFR stage worsened. The P-SEP / CRE ratio became significantly higher in sepsis pa-
tients and was a more useful index with a reference range of 67–263. Conclusions : P-SEP levels were inversely 
correlated with renal function, indicating the necessity to consider the influence of renal impairment in CKD 
patients. The P-SEP / CRE ratio is helpful for sepsis diagnosis, even in patients with renal impairment. J. Med. 
Invest. 68 : 105-111, February, 2021
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INTRODUCTION
 
Sepsis is a disease that results in a systemic inflammatory 
response syndrome (SIRS) due to an uncontrolled host response 
to infection. Severe sepsis with organ failure or shock has a 
high mortality rate, and early diagnosis and intervention are 
important (1, 2). However, SIRS is not only associated with 
infection. Therefore, it is necessary to accurately distinguish 
between septic SIRS and non-infectious SIRS caused by trauma 
or burns ; consequently, it is essential to diagnose the underlying 
causative infectious disease. However, it takes several days to 
receive the results of bacterial culture tests, and the tests are 
not always positive. Therefore, biomarkers that can specifically 
diagnose sepsis have been investigated.
In 1993, it was reported that the level of procalcitonin (PCT), a 
precursor of calcitonin, was elevated in sepsis patients (3), and it 
has been widely used as an index for diagnosis and evaluation of 
therapeutic effects (4-6). However, PCT has certain drawbacks, 
such as high values even in non-infectious inflammation or trau-
ma cases and difficulty in describing the clinical course (7, 8).
Presepsin (P-SEP) is a glycoprotein composed of approximate-
ly 70 amino acids, which was discovered in 2002, and is used as 
a specific biomarker for sepsis (9, 10). Various clinical studies 
have been conducted to explore its usefulness. Unlike existing 
biomarkers, such as PCT, P-SEP exhibits a very weak response 
to inflammation due to trauma and burns. It is very specific for 
bacterial infections (7, 8, 10-12) as it shows a rapid increase. 
Additionally, it is responsive to changes in patients’ medical con-
ditions and reflects the effect of treatment. 
However, P-SEP has a molecular weight of 13 kDa, which is 
comparable to that of cystatin C (Cys-C). As reported by Nagata 
et al. (13) and verified by Miyoshi et al. (14), the kidney is the 
main excretion organ of P-SEP. Therefore, P-SEP is elevated in 
patients with kidney disease, such as those undergoing dialysis. 
High P-SEP levels due to renal impairment may lead to incorrect 
diagnosis, and this should be considered when diagnosing sepsis 
in patients with chronic kidney disease (CKD). Thus, there is 
a need for renal function-corrected indices. Furthermore, for 
P-SEP measurement, the manufacturer’s protocol advises that 
the intensity of agitation during blood collection and transpor-
tation affect the results. This influence of agitation and trans-
portation is not recognized in clinical settings. Therefore, it is 
possible that false high values are reported in clinical practice 
or research.
In this study, we analyzed the relationship between P-SEP 
levels and renal function by standardizing the blood collection 
procedures to minimize the influence of stirring. Moreover, we 
evaluated the usefulness of presepsin / creatinine (P-SEP / CRE) 
ratio as a new index that corrects for renal function.
PATIENTS AND METHODS
Selection and description of participants
Eighty-five outpatients with CKD who visited Tokushima 
University Hospital between May and September 2017 were 
enrolled in this study. None of the enrolled patients had a history 
of dialysis or symptoms of infection. Infection was diagnosed by 
physicians based on clinical manifestations or laboratory results. 
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We confirmed that the involved patients with estimated glomer-
ular filtration rate (eGFR) > 60 mL / min / 1.73 m2 had kidney 
abnormalities such as albuminuria, urine sediments, electrolyte, 
and other abnormalities due to tubular disorders, abnormalities 
detected by histology, or structural abnormalities detected by 
imaging. The abnormalities were present for more than three 
months.
Blood samples and data were collected from 4 patients with 
sepsis and 65 healthy volunteers (hereafter, normal group) 
consisting of doctors, clinical laboratory technicians, and med-
ical students who were recruited from our institute. For the 4 
patients with sepsis, the first blood sampling was performed at 
the time when the physician diagnosed sepsis, thereafter, blood 
sampling was performed daily for up to 5 days of illness to ob-
tain a total of 19 samples. The non-infected group included 150 
patients, including CKD patients and normal group. Data of the 
clinical characteristics of the participants and sepsis patients 
are shown in Table 1.
Informed consent was obtained from all the patients and 
volunteers after written information provision. Permission for 
this study protocol and consent procedure were approved by the 
Ethics Committee at Tokushima University Hospital (No. 2699), 
and this study was performed in compliance with the Helsinki 
Declaration. 
Blood collection, biochemical analysis, and samples
As P-SEP levels are increased by strong agitation, blood 
samples after completing blood count measurements cannot be 
used. Thus, samples were collected separately into EDTA-2K 
blood collection tubes for P-SEP measurements. At the time of 
blood sampling, five gentle inversions were performed. The blood 
sample was transported in a manner that prevented agitation, 
and the tests were conducted within 10 mins of blood collection. 
The eGFR of each participant was calculated using the equa-
tion provided by the Japanese Society of Nephrology as follows :  
eGFRcreat (mL / min / 1.73 m2) = 194 × creatinine (mg / dL)-1.094 
× age-0.287 (if female, × 0.739) (15)
The GFR was categorized according to the Kidney Dis-
ease : Improving Global Outcomes (KDIGO) 2012 guidelines 
(16).
Technical information 
P-SEP levels were measured by a rapid automated immu-
noanalyzer, “PATHFAST” (LSI Medience Corporation, Tokyo, 
Japan), based on a chemiluminescent enzyme immunoassay. 
The reference range of the P-SEP / CRE ratio was calculated 
using a non-parametric method. All values were listed in order 
according to the Clinical and Laboratory Standards Institute 
guidelines. Values of 2.5–97.5% were used as the reference 
range. Excision of extremes was not performed (17). 
Statistical analysis
All values are shown as mean ± standard deviation (SD). The 
results were analyzed using Student’s paired T test for compar-
ison between two groups. The Kruskal–Wallis test along with 
the Bonferroni post hoc test was used for multiple comparisons. 
Statistical analyses were performed using EZR (Saitama Med-
ical Center, Jichi Medical University, Saitama, Japan) (18). A P 
value < 0.05 was considered to be significant.
RESULTS
Influence of agitation on P-SEP measurements
To confirm the influence of agitation due to mixing with in-
version, the number of inversions during blood collection was 
increased from 5 to 30 occurrences in 10 healthy volunteers. 
The fluctuation of P-SEP levels was confirmed. Furthermore, 
if strong agitation and impact were applied, samples were ana-
lyzed that were sent by an air shooter used for transportation of 
Table 1.　Clinical characteristics of participants in the different GFR categories and sepsis patients
Normal G1 G2 G3 G4 G5 Sepsis
N 65 15 19 26 15 10 4 (19 samples)
Age 33.2 ± 11.8 36.8 ± 10.2 57.6 ± 13.9 59.7 ± 15.7 61.3 ± 13.1 66.9 ± 12.8 68.3 ± 12.0
Male, n (%) 31 (47.7) 8 (53.3) 14 (73.7) 19 (73.1) 10 (66.7) 6 (60.0) 2 (50.0)
Body surface area (m2) 1.612 ± 0.18 1.767 ± 0.22 1.677 ± 0.18 1.727 ± 0.20 1.677 ± 0.23 1.556 ± 0.15 NA
AST (U / L) 18.1 ± 5.9 24.4 ± 14.9 20.8 ± 5.9 25.1 ± 9.0 20.0 ± 6.0 20.2 ± 7.5 179.1 ± 224.9
ALT (U / L) 15.9 ± 14.9 23.8 ± 13.0 17.4 ± 7.8 23.0 ± 11.3 13.2 ± 4.6 14.5 ± 4.1 97.0 ± 94.5
Creatinine (mg / dL) 0.722 ± 0.15 0.624 ± 0.09 0.834 ± 0.13 1.307 ± 0.33 2.218 ± 0.50 4.956 ± 2.27 2.648 ± 2.05
Blood urea nitrogen (mg / dL) 13.4 ± 3.1 10.9 ± 2.5 14.8 ± 3.5 21.7 ± 7.8 33.0 ± 8.4 55.4 ± 19.0 NA
eGFRcreat (mL / min / 1.73 m2) 91.0 ± 12.5 102.9 ± 10.6 69.9 ± 6.8 43.8 ± 10.5 23.5 ± 3.5 10.4 ± 3.4 43.4 ± 43.3
White blood cells (×109  / L) 5.6 ± 1.2 6.9 ± 2.8 6.1 ± 1.2 5.9 ± 1.4 5.2 ± 1.6 6.3 ± 2.1 11.1 ± 6.4
Hemoglobin (g / dL) 13.6 ± 1.4 14.6 ± 1.3 13.5 ± 1.9 13.7 ± 1.7 12.3 ± 1.3 10.9 ± 1.3 8.7 ± 2.7
Hematocrit (%) 41.0 ± 4.1 43.2 ± 3.3 39.6 ± 4.7 40.2 ± 4.6 36.5 ± 3.7 33.3 ± 3.3 30.0 ± 4.7
Platelets (×109 / L) 248.8 ± 49.1 276.1 ± 72.5 240.1 ± 49.2 237.7 ± 49.7 312.5 ± 399.2 191.2 ± 42.1 103.7 ± 41.6
Data are presented as means ± standard deviation and as numbers (%).
Estimated glomerular filtration rate (eGFR) values were categorized by eGFRcreat according to the KDIGO 2012, as follows : G1 : 
eGFRcreat ≥ 90 mL / min / 1.73 m2; G2 : eGFRcreat = 60–90 mL / min / 1.73 m2 ; G3 : eGFRcreat = 30–60 mL / min / 1.73 m2; G4 : eGFRcreat = 
15–30 mL / min / 1.73 m2 ; and G5 : eGFRcreat ≤ 15 mL / min / 1.73 m2.
AST, aspartate transaminase ; ALT, alanine transaminase ; eGFRcreat, estimated glomerular filtration rate calculated using creati-
nine values; NA, not available.
107The Journal of Medical Investigation   Vol. 68  February  2021
samples between wards. 
Therefore, the average value ± SD for healthy subjects with 
five gentle inversions was 82 ± 13 pg / mL. The average values ± 
SD when the number of inversions was set at 10, 20, and 30 were 
100 ± 18 pg / mL, 117 ± 21 pg / mL, and 137 ± 23 pg / mL, respec-
tively. The larger number of inversions caused the higher levels 
of P-SEP. Samples sent using an air shooter showed a remark-
able increase of 290 ± 81 pg / mL (Fig. 1).
Stratified comparison in CKD patients
In CKD patients, P-SEP levels were stratified by GFR 
stage classified using eGFRcreat (Fig 2). P-SEP levels in each 
group were as follows : normal : 96.4 ± 27.0 pg / mL, CKD stage 
G1 : 104.8 ± 32.0 pg / mL, CKD stage G2 : 124.7 ± 46.7 pg / mL, 
CKD stage G3 : 182.2 ± 92.4 pg / mL, CKD stage G4 : 265.4 ± 
155.6 pg / mL, and CKD stage G5 : 660.6 ± 357.4 pg / mL. P-SEP 
levels were significantly higher in CKD stage G3 patients than 
in normal patients and became higher in patients with an ad-
vanced GFR stage. 
In contrast, in patients with CKD stages G1 and G2 for whom 
renal function was preserved, there was no significant difference 
in P-SEP levels between patients and the normal group.
Evaluation of possible indices that correct for renal function
To establish a new index considering renal function, we at-
tempted correction using creatinine or eGFR. The creatinine-cor-
rected P-SEP / CRE ratio and eGFR-corrected P-SEP / eGFR, 
which were corrected to creatinine : 1.0 mg / dL and eGFR : 100 
mL / min / 1.73 m2, were calculated in the normal group to com-
pare with uncorrected P-SEP levels. A P-SEP value of 96.4 ± 
27.0 pg / mL corresponded to a coefficient of variation (C.V.) of 
28.0%. A P-SEP / CRE ratio of 139.6 ± 49.7 had a C.V. of 35.6%. 
Finally, a P-SEP / eGFR value of 86.8 ± 23.4 had a C.V. of 27.0%. 
The P-SEP / CRE ratio was high, and the distribution width was 
large. In contrast, P-SEP / eGFR was almost the same as the 
uncorrected P-SEP levels, and the distribution width was small 
(Fig. 3).
 
Stratified comparison of P-SEP / CRE ratio
The stratified comparison of P-SEP / CRE ratio was performed 
for the normal group and CKD patients as classified by eGFR-
creat. The following values were obtained : normal : 139.6 ± 49.7, 
CKD stage G1 : 172.41 ± 60.2, CKD stage G2 : 150.6 ± 55.4, CKD 
stage G3 : 136.9 ± 45.5, CKD stage G4 : 122.4 ± 66.6, and CKD 
stage G5 : 139.9 ± 63.0. On comparison of P-SEP / CRE ratio 
according to GFR stage, there was no increase in patients with 
advanced GFR stage, and no difference was observed between 
the normal group and CKD patients (Fig. 4). 
 
Stratified comparison of P-SEP / eGFR
The results of the stratified comparison of P-SEP / eGFR 
are now given. Normal was 86.8 ± 23.4, CKD stage G1 was 
108.0 ± 34.8, CKD stage G2 was 87.0 ± 33.6, CKD stage G3 was 
73.1 ± 22.9, CKD stage G4 was 60.9 ± 33.1, and finally CKD 
Fig 1.　Influence of agitation on presepsin measurements. P value 
calculated using the paired t test
Fig 2.　Presepsin levels in the normal group and in patients with 
chronic kidney disease 
The GFR stage is classified using eGFRcreat. P value calculated using 
the Kruskal–Wallis one-way analysis of variance. P value adjustment 
performed using the Bonferroni method
Fig 3.　Evaluation of possible indices that correct for renal function. 
P-SEP / CRE ratio = presepsin / creatinine. P-SEP / eGFR = presepsin × 
eGFR / 100
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stage G5 was 63.4 ± 32.3. There was a significant decrease in 
patients with an advanced GFR stage (Fig. 5).
 
Renal function-corrected indices in sepsis patients
P-SEP levels and two renal function-corrected indices were 
compared between sepsis patients and non-infected group, includ-
ing normal group and the enrolled CKD patients. The following 
index values were obtained in the patients with sepsis : P-SEP, 
4772.0 ± 3856.8 pg / mL ; P-SEP / CRE ratio, 1859.1 ± 655.2 ; and 
P-SEP / eGFR, 954.4 ± 389.4. 
All indices were significantly higher in sepsis patients than 
in non-infected group. Additionally, when the P-SEP / CRE ratio 
was used, the difference in the values between sepsis patients 
and non-infected group was greater (Fig. 6).
 
Calculation of a reference range for the P-SEP / CRE ratio
A total of 150 P-SEP / CRE ratio values derived from the 
non-infected group were used to determine the reference range 
of P-SEP / CRE ratio. The P-SEP / CRE ratio in the non-infected 
group ranged from 50.8 to 308.9. A value between the 2.5th per-
centile and the 97.5th percentile was used as the reference range. 
The calculated reference range was 67–263 (Fig. S1).
Fig 4.　Stratified comparison of P-SEP / CRE ratio. The GFR stage 
is classified using eGFRcreat. P value calculated using the Kruskal–
Wallis one-way analysis of variance. P value adjustment performed 
using the Bonferroni method
Fig 5.　Stratified comparison of P-SEP / eGFR. The GFR stage is 
classified using eGFRcreat. P value calculated using the Kruskal–
Wallis one-way analysis of variance. P value adjustment performed 
using the Bonferroni method
Fig 6.　The P-SEP / CRE ratio or P-SEP / eGFR in the non-infected group and sepsis patients. P value calculated using the Kruskal–Wallis one-
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DISCUSSION
P-SEP is useful as a rapid and specifically elevated marker 
of sepsis. However, it may show falsely high values because of 
renal function and agitation. None of the previous studies have 
considered the influence of sample agitation. In this study, we 
analyzed the effect of renal function on P-SEP measurement by 
minimizing the influences of agitation and transport. Moreover, 
the P-SEP / CRE and P-SEP / eGFR ratios were examined as 
possible indices that correct for renal function. Subsequently, it 
was found that the P-SEP / CRE ratio was more useful as a new 
renal function-corrected index. These ratios can facilitate the 
diagnoses of sepsis in patients with renal impairment. 
In the stratified comparison using eGFRcreat in CKD pa-
tients, P-SEP levels showed a significant increase in accordance 
with an increase in the GFR stage. P-SEP levels in patients with 
mild renal impairment up to CKD stage G2 were not signifi-
cantly different from those in healthy volunteers. In contrast, 
in patients with CKD stage G3 or higher renal impairment, 
significantly higher P-SEP levels were observed. This was also 
true in non-infected cases. Sepsis diagnosis is not based on only 
one biomarker but is also a comprehensive diagnosis based on 
multiple markers and clinical symptoms. P-SEP levels must be 
carefully interpreted to diagnose sepsis in patients with renal 
impairment. 
To correct the effect of renal function and improve the ability 
to diagnose sepsis in CKD patients at a high risk of infection, 
new indices, such as P-SEP / CRE ratio and P-SEP / eGFR, were 
evaluated. When the stratified comparison of P-SEP / CRE ratio 
was performed, high P-SEP levels due to renal impairment 
disappeared in all the CKD grades, and P-SEP levels showed 
equivalent levels. In contrast, in the stratified comparison of 
P-SEP / eGFR, the increasing trend of P-SEP levels due to renal 
impairment was absent. However, P-SEP / eGFR showed a de-
creasing trend. The eGFR formula is not recommended to apply 
in a normal group owing to large errors (15). In patients with 
normal renal function, the eGFR correction can be inadequate.
The same evaluation was also performed using eGFR, consid-
ering the body surface area of an individual. This resulted in a 
similar tendency as eGFR. Therefore, the superiority of using 
individual eGFR was not observed (data not shown). 
Regarding P-SEP / Cys-C ratio, increasing trend was not ob-
served with advanced GFR stage (Fig. S2). However, we could 
not find the advantage of P-SEP / Cys-C ratio over P-SEP / CRE 
ratio because Cys-C measurements were covered by health in-
surance in Japan only for patients with renal impairment with 
a frequency of once every three months (19). Additionally, Cys-C 
is a sensitive indicator of early-stage renal failure, whereas it 
reaches a plateau in patients with end-stage renal failure ; there-
fore, it does not accurately reflect renal function in end-stage 
renal disease.
Moreover, in sepsis patients, both the P-SEP / CRE ratio and 
P-SEP / eGFR indicated a remarkably high value in all samples, 
regardless of the presence or degree of renal impairment and sig-
nificant differences from those in the non-infected group. There-
fore, the diagnostic ability was maintained as well as it was at 
uncorrected P-SEP levels. The difference in P-SEP / CRE ratio 
between sepsis patients and the non-infected group was larger 
than that of P-SEP / eGFR, suggesting the P-SEP / CRE ratio is 
Fig S1.　Distribution of P-SEP / CRE ratio. P-SEP / CRE ratio = presepsin / creatinine.
Fig S2.　Stratified comparison of P-SEP / Cys-C ratio. The GFR stage 
is classified using eGFRcreat. P value calculated using the Kruskal–
Wallis one-way analysis of variance. P value adjustment performed 
using the Bonferroni method
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more useful to diagnose sepsis.  Nakamura et al., reported sepsis 
cases in CKD patients (20). They concluded that P-SEP level can 
be a reliable indicator of sepsis not only among non-acute kidney 
injury (AKI) patients but also patients with less severe forms 
of AKI. However, it may not be a reliable indicator of sepsis in 
patients with a more advanced form of AKI. We need more sepsis 
cases in CKD patients to validate the P-SEP / CRE ratio by han-
dling the blood samples with an appropriate procedure. 
Although the correction of renal function was possible using 
both indices, the P-SEP / CRE ratio was simpler, more applicable, 
and useful. Consequently, we calculated the reference standard 
range for the P-SEP / CRE ratio using data from non-infected 
groups, which was 67–263. The cutoff value for uncorrected 
P-SEP levels was less than 400–700 (mean : 500 pg / mL : Japan 
(21)), although the index was different ; the P-SEP / CRE ratio 
could be applied without changing the prevailing clinical criteria.
This study revealed that P-SEP levels were increased by 
increasing the number of inversions, even with gentle stirring. 
Further, it was confirmed that when an impact by an air shooter 
was applied, remarkably high values were observed. The cause 
of falsely high values is presumed to be a cross-reaction of the 
anti-P-SEP antibody with an unknown macromolecular complex 
formed by stimulation such as stirring ; however, the formation 
mechanism, reactivity with reagents, and other possible causes 
of false high values are still unknown. Since the measurement 
of P-SEP is directly linked to diagnosis and treatment, the fluc-
tuation by blood sampling procedures or transport conditions 
is an issue that cannot be overlooked. Therefore, it is necessary 
to unify blood collection and transport procedures along with 
thoroughly disseminating information regarding this issue to 
doctors and nurses.
This study has some limitations. First, it is possible that en-
rolled CKD patients had a hidden infectious disease because this 
diagnosis was based on physical assessment. Second, there was 
a difference in age between the normal group and CKD patients. 
Third, we performed blood tests on healthy volunteers, but we 
did not evaluate the other abnormalities, such as albuminuria, 
urine sediments, and structural abnormalities. 
In conclusion, by excluding the influence of stirring during 
blood sampling, our study demonstrated that P-SEP levels in-
crease as GFRs decrease. CKD for stage G1 and G2 groups can 
be evaluated in the same way as that for the normal group ; how-
ever, in patients with CKD stage G3 or higher, even non-infected 
patients need to be evaluated carefully. The P-SEP / CRE ratio 
makes it possible to correct for renal function and is a useful and 
simple new index for sepsis diagnosis that could contribute to 
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